Evotec and Odyssey Therapeutics enter AI-enabled R&D collaboration in autoimmune and inflammatory diseases

Evotec and Odyssey Therapeutics announced on 6 August 2026 an AI-enabled research and development collaboration targeting autoimmune and inflammatory diseases.

The partnership pairs Odyssey's disease-biology and target expertise with Evotec's integrated drug-discovery platform and AI-driven capabilities to accelerate the identification of promising small-molecule drug candidates against a defined set of targets. Under the terms disclosed, Evotec is eligible to receive milestone payments tied to the successful delivery of validated hit series for each target, aligning value creation with early research progress.

The deal deepens Evotec's positioning as a European AI-biotech discovery engine and adds an early-stage immunology-focused programme to Odyssey's pipeline.

Source: Evotec, 6 August 2026.